Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

  • August 2017 •
  • 39 pages •
  • Report ID: 5148517

Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines and T-Cells 2017
This Competitive Intelligence report about Mesothelin-Targeted Antibodies, Vaccines and T-Cells 2017 provides a competitor evaluation in the field of antibodies, vaccines and engineered chimeric antigen receptor (CAR) T-cells targeting mesothelin as of August 2017.

 Mesothelin is a surface marker protein overexpressed in many cancers and is a suitable target for directing immunotherapeutics to mesothelin expressing tumors, such as malignant pleural mesothelioma, mesothelioma and pancreatic, non-small cell lung, ovarian, endometrial and gastric cancers.

The report includes a compilation of currently active projects in research and development of antibodies, vaccines and engineered T-cells directed against mesothelin. In addition, the report lists company- and institution-specific RandD pipelines of anti-Mesothelin Immunotherapeutics.

Competitor projects are listed in a tabular format providing information on:
  • Drug Codes
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • RandD Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of RandD projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Industry=Cancer ParentIndustry=Pathology Date=201708 Topic=MarketReport Publisher=LaMeriePublishing Price=1000